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1. Introduction
The discovery of liposomes initially came from studies by Bangham and Horne who observed
by electron microscopy the self-association of the lipid phosphatidylcholine (mixed with or
without cholesterol) in water formed ‘spherulites’ of varying sizes which had not a recogniz‐
able lamellar shell comprising a lipid bilayer [1]. The self-assembling ‘spherulites’, subse‐
quently named liposomes from the greek lipo (fat) and soma (body), were recognised to be
functionally analogous to studied biological membrane systems due to the similar rates of
diffusion of ions [2]. However only when an ionophore, valinomycin, was utilised demon‐
strating selective diffusion of K+ over Na+ from liposomes containing equal concentrations of
the ions, could liposomes be confirmed as entirely sealed membrane vesicles [3]. Furthermore
Papahadjopoulos and Watkins showed the differential permeability to anions and cations
could be significantly altered with liposomes of different phospholipid compositions [4].
Natural liposomes have bilayers composed of phospholipids and/or cholesterol and as such
are poorly antigenic, typically non-toxic and physiologically inert. Liposomes can vary in size
from 25 nm to 2.5 µm and are classified within three broad categories [5]: Multilamellar vesicles
(MLV), which structurally resemble an onion with multiple concentric phospholipid bilayers
separated by aqueous layers,large unilamellar vesicles (LUV) and small unilamellar vesicles
(SUV) which have a single lipid bilayer surrounding the aqueous core. Typically multiple
unilamellar vesicles of differing sizes can form inside of each other generating multilamellar
structures.
The concept of liposomes as drug-carriers to aid in selectivity was explored in the early
nineteen seventies predominantly through the work of drug-transport scientists such as
Gregoriadis who initially looked at the fate of protein-containing liposomes delivered into
animals [6]. The theory that liposomes stay intact and circulate in the bloodstream before
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accumulating in specific tissues where they release their molecules into cells was confirmed
using radiolabelled proteins entrapped in liposomes. The radioactive signal from the proteins
was barely detected in the bloodstream, but predominantly in the lysosomes of cells of the
liver and spleen, showing the liposomes stayed intact prior to the radiolabelled proteins being
taken up by the cells. This and related studies revealed the physiological behaviour of
liposomes such as their integrity and long life span in the mammalian bloodstream. It was only
through the use of cell culture it was confirmed that cargo carried by liposomes was directly
delivered through endocytosis into the lysosomes and thus into the intracellular environment
of cells [7]. These initial studies demonstrated the huge potential for liposomes as model
systems, and a number of various applications were subsequently explored as listed here: The
effect of surface charge on ion permeability [8]; their susceptibility to phospholipase hydrolysis
[9]; the function of integral membrane ion transporters [10]; the delivery of active enzymes to
functionally deficient cells [11]; their use as immunological adjuvants [12]; as stimulants of
interferon production [13]; their interaction with polyene antibiotics [14]; their incorporation
of local and general anaesthetics [15]; the inclusion and presentation of virus surface proteins
[16]. Since those early experiments, there has been a continued interest in the use of liposomes
and currently there are applications in a wide variety of scientific fields (Figure 1).
In this chapter we will focus on the use of lipids and liposomes in the enhancement of a number
of health related areas and cover the development of new synthetic molecules, which have
great potential in advancing improvements in health and the treatment of disease.
Figure 1. A schematic representation of a liposome. The liposome can facilitate the carrying of various cargo, water-
soluble drugs, DNA or RNA, in the internal hydrophilic region, water-insoluble drugs within the hydrophobic region
of the bilayer, or protein linked or incorporated into the phospholipid bilayer.
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2. Current applications in treating disease
2.1. Non-communicable diseases
It is evident that with their physiological attributes, liposomes are an attractive means to
deliver drugs to treat a variety of communicable and non-communicable diseases. Typically,
drugs for the treatment of human diseases can often have a number of biochemical and
pharmacological issues such as poor stability and solubility, rapid breakdown and lack of
targeted delivery. As a result there are common problems in the use of such drugs, including
the lack of a strong therapeutic cure and the necessity to consume high doses, which can result
in unwanted side effects. If the disease is localised to a specific body tissue, the lack of selective
targeting can result in poor bioavailability of the drug at the required site, potentially resulting
in toxicity in other tissues, thus restricting the dose concentration. The use of natural phos‐
pholipid based liposome formulations having minimal toxicity, extended stability in the
human body, tissue selectivity and a delayed release of the active compound at the site of
action suggests clear benefits for drug development and treatment. In addition multiple
compounds can be distributed by the same liposomes for added therapeutic impact. Equally,
compounds of varying lipophilicities can transported, partitioning in the different hydropho‐
bic and hydrophilic environments of the liposomes. Particle size is a critical factor both in the
circulatory half-life of liposomes and also (along with the number of bilayers) dictates the
amount of encapsulated drug [17]. In general, drug delivery systems are on the nanoscale,
liposomes having diameters of 100 nm or less tend to have a good therapeutic index compared
to conventional anticancer therapies. Typically liposomes for drug therapies approved for
humans contain the neutrally charged phosphatidylcholine as the major membrane constitu‐
ent, though occasionally cholesterol (up to a third of the total lipid content) is incorporated to
reduce membrane instability due to serum protein binding. Thirty years ago, the application
of liposomes to deliver an anti-cancer anthracycline drug doxorubicin trapped in negatively
charged or neutral liposomes (called OLV-DOX) showed that it retained its antitumour activity
in mice [18]. Importantly the use of the liposomal formulation reduced the accumulation of
the drug in murine cardiac tissues, minimising toxicity and thus significantly improving their
survival. When tested in humans however the OLV-DOX worked poorly, being rapidly cleared
from the bloodstream with significant premature release of the drug, giving rise to potential
cardiotoxicity [19]. These failings limited the application of liposomes in cancer treatment at
that time, only resolved by the subsequent experimental trialling of polyethylene glycol (PEG)
incorporation in phospholipid liposomes. The PEG was found to create a hydrophilic surface
on the liposomes, reducing uptake by the reticuloendothelial system and thus increasing the
circulation time of these so-called ‘stealth’ liposomes. This resulted in a revolution in liposome
design and so in 1995 Doxil (PEGylated liposome-trapped doxorubicin) the first of the so-called
2nd generation was approved by the US Food and Drug Administration as the first liposome
drug delivery system for human use [20]. Doxil was found to have extended stability in the
bloodstream and reduced compound leakage resulting in increased accumulation in solid
tumours (up to 22-fold) and reduced toxicity to non-target organs. Every year over 300,000
patients with ovarian cancer or Kaposi’s sarcoma are now routinely intravenously treated with
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Doxil [21] and it is occasionally utilised in cases of breast cancer and also in combination with
bortezomib for multiple myeloma.
Alongside Doxil, to date five other liposomal formulations are approved for human cancer
treatment (Table 1). Myocet, a related non-PEGylated liposome formulation of doxorubicin is
used in combination with cyclophosphamide for breast cancer [22]. DaunoXome, a liposome
formulation of daunorobicin is similarly used to treat Kaposi’s sarcoma [23]. DepoCyt, a
formulation of unusually large liposomes containing cytarabine is active against malignant
lymphomatous meningitis [24], while Marqibo is a more typical nanoscale formulation of
liposomes of vincristine utilised for acute lymphoblastic leukemia [25]. Recently, more success
has come from the trial use of such liposome formulations in combination with standard anti-
cancer drugs, one example being a Doxil and carboplatin composition which shows a better
therapeutic index and less toxicity than the standard paclitaxel/carboplatin mixture used to
treat ovarian cancer in the elderly [26]. Similarly in comparison to a standard treatment, a
combination of Doxil, bortezomib and dexamethasone showed a strong therapeutic response
and improved tolerability in patients with multiple myeloma [27].
Market Product Drug used Target diseases Company
Doxil or Caelyx Doxorubicin Kaposi’s sarcoma SEQUUS, USA
DaunoXome Daunorubicin Kaposi’s sarcoma, breast
& lung cancer
NeXstar, USA
Amphotec Amphotericin-B Fungal infections,
Leishmaniasis
SEQUUS, USA
Ventus Prostaglandin-E1 Systemic inflammatory
diseases
The liposome company, USA
Alec Dry protein free powder of
DPPC-PG











Killed avian retrovirus Chicken pox Vineland lab, USA
Novasome Smallpox vaccine Smallpox Novavax, USA
Depocyt Cytarabine Cancer therapy Skye Pharm, USA
Topex-Br Terbutaline sulphate Asthma Ozone, USA
Table 1. Current products utilising liposomes
A major issue in cancer treatments is the failure of many forms of chemotherapy due to the
phenomenon of multidrug resistance. As a result, the tactic of using drug combinations has
become widely adopted due to the greater therapeutic index and efficacy in reversing the
multidrug resistant phenotype [28]. In a combination treatment drugs can have one of three
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effects, synergistic, additive or antagonistic and this can be shaped by their specific molar ratios
in the formulation [29]. Unfortunately in an in vivo setting, the combinatorial effect can be
weakened due to disrupted pharmacokinetics of the drugs in the system, leading to incorrect
dose ratios at the site of action [30]. Based on prior research, it was clear that the pharmacoki‐
netic issues of combination therapies can be eliminated by the use of liposome formulations,
resulting in delivery of the drugs to their site of action at the correct effective ratio [31]. Equally
important in the enhancement of health is the use of liposomes in the treatment of cardiovas‐
cular disease, the leading cause of deaths worldwide. Again relatively early in liposome
research, it was observed that liposomes carrying the MRI contrast agent 99mTc-DTPA
accumulated in regions of the heart experimentally induced to undergo myocardial infarction
(MI), a common cause of death [32]. In MI, during the ischemic phase, the exhaustion of
nucleotide pyrophosphates causes extensive myocardial cell damage [33]. The obvious
solution, the infusion of adenosine triphosphate (ATP) intravenously to increase myocardial
cell energy levels is sub-optimal due to the molecule’s short circulatory half-life and strong
charge. The relatively unstable ATP could however be protected and successfully delivered
using liposomes and clearly accumulated in canine myocardia damaged by ischemia [34].
Subsequently it was discovered that targeted ATP-containing liposomes can significantly
protect against the subsequent effects of ischemia in an ex vivo rat heart model [35]. When
translated into an animal model, ATP-loaded liposomes reduced the amount of irreversible
myocardial damage by greater than 50% compared to control treated rabbits [36].
Another significant agent in the prevention and treatment of ischemic injury and indeed heart
failure, coronary artery disease and hypertension in general, is Coenzyme Q10 (CoQ10) [37].
Evaluation of CoQ10 loaded liposomes again in the aforementioned rabbit model revealed
that only 30% of the affected myocardia was at risk of irreversible damage compared to the
control, indicative of significant protection and great potential in this approach [38]. In
humans, the use of large-scale trials of adenosine on clinical patients with acute MI has shown
some promise but again is a poor compound with a short half-life and hypotensive and
brachicardic inducing properties [39]. These issues may be overcome based on an experimental
study using PEGylated liposomes of adenosine which generated non-toxic and cardioprotec‐
tive effects against MI in rats [40]. In treating another common cause of ischemic damage,
thrombus formation, a range of thrombolytic drugs have been developed. Due to its need for
constant infusion and potential to cause haemorrhage, one of the first thrombolytic drugs,
heparin was quickly assessed in a liposomal formulation [41]. Liposomal heparin was much
more effective in its thrombolytic effects, being retained in the plasma longer and generated a
prolonged activity due to a gradual release of the agent. Ultimately an inhalable formulation
successfully replaced the intravenous version in rat models of deep vein thrombosis and
pulmonary embolism giving promise to future clinical trials [42].
2.2. Communicable diseases
As significant as the development of liposomes in the treatment of non-communicable human
diseases has been, the field of anti-parasitic drug development generated the first liposomal
formulation to be mass marketed. With no vaccines effective against any of the primary
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parasitic infections, anti-parasitic drug treatment remains the main approach. Many current
anti-parasitic compounds were developed over 50 years ago and though effective, are hardly
comparable to the modern view of the biochemical and clinical properties of an ideal drug.
Due to the fact that many anti-parasitic drugs have solubility issues, low bioavailability and
poor absorption by the gastrointestinal tract, it was an obvious choice to test the potential of
liposomes for anti-parasitic drug delivery. AmBisome, a natural liposome configuration of the
potent anti-leishmanial amphotericin B was the first liposome drug based formulation to be
commercialised in 1990 (Table 2) [43]. A sterol biosynthesis inhibitor, amphotericin B is the
standard second-line treatment for visceral leishmaniasis (caused by Leishmania donovani) and
is essential in endemic disease areas in India due to the extensive development of resistance
against the standard pentavalent antimonial compounds [44]. AmBisome is particularly
effective against Leishmania (2 to 5-fold more potent than the free drug) due to the fact that the
parasite infects the very macrophages which clear the liposomes from the bloodstream,
increasing the therapeutic effect and additionally reducing the nephrotoxicity of amphotericin
B. Initially liposomes containing antimonial compounds were tested in a hamster model of
visceral leishmaniasis and were greater than 700 fold more active than the free drug version
showing the significant potential of liposome use [45]. Interestingly antimonial encapsulated
liposomes were also shown to be potent against cutaneous leishmaniasis where the parasites
alternatively reside in peripheral tissues [46].
Drug Route of Administration Targeted Diseases
Amphotericin-B Oral Mycotic infection, Leishmaniasis
Insulin Oral, Ocular, Pulmonary and Transdermal Diabetic mellitus
Ketoprofen Ocular Pain muscle condition
Pentoxifylline Pulmonary Asthma
Salbutamol Pulmonary Asthma
Tobramycin Pulmonary Pseudomonas infection, aeruginosa
Benzocain Transdermal Ulcer on mucous surface with pain
Ibuprofen Oral Rheumatoid arthritis
Adrenaline Ocular Glucoma, Conjectivitis
Penicillin G Pulmonary Meningococal, staphylococcal
Methotrexate Transdermal Cancer
Table 2. Therapeutic applications utilising liposomes
While AmBisome remains the only liposomal antiparasitic agent on the market, other liposome
formulations have been developed showing potency against Leishmania spp. Liposomes
modified with sugars improved the targeting of antileishmanial pentamidine to infected
macrophages with increased potency as a result [47]. Similarly, delivery of the alkylphospho‐
lipid miltefosine (hexadecylphosphocholine) in a liposomal form proved twice as active
against L. donovani and actually even increased the susceptibility of a miltefosine-resistant
parasite line [48]. Far less exploration has been done to assess the value of liposomal agents
against the causative agents of Human African Trypanosomiasis (HAT) and Chagas’ disease,
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Trypanosoma brucei and Trypanosoma cruzi respectively. Both species of parasite have dissem‐
inating infections and localise to tissues of the body where there is limited interaction with
liposomes. However a number of in vitro and in vivo studies using liposomes have evaluated
potential anti-trypanosomal effects. Two related investigations demonstrated that phospha‐
tidylcholine/stearylamine only liposomes at low concentrations (100 µM) non-toxic to eryth‐
rocytes, rapidly killed both T. cruzi [49] and T. brucei [50] through destabilization of their
plasma membranes. Notably this effect was not seen with identical concentrations of the
individual lipid components, suggesting the vesicle structure was important for activity. The
surprising failure of liposomes containing benznidazole to improve on the potency of this
classical anti-T. cruzi treatment was hypothesised to be due to a lack of drug delivery [51],
though the anti-leishmanial AmBisome demonstrated some success in supressing T. cruzi
infections in vivo [52].
With so many anti-malarial drugs commercially available and in development, the focus of
liposome development in this field is on the protection of drugs from premature metabolism,
to generate a slow release to improve the therapeutic index and reduce toxicity. To this end,
liposomes of Artesunate, a semi-synthetic derivate of artemisinin, were found to release only
30% of the drug in 24 h in an in vitro test, giving promise to this method as a means to reduce
the dosing frequency of antimalarial drugs [53]. In a rabbit model, Arteether directed for
chloroquine resistant Plasmodium falciparum, when trapped in dipalmitoylphosphatidylcho‐
line, dibehynoylphophatidylcholine, cholesterol liposomes persisted longer with greater
bioavailabilty in the gastrointestinal tract when compared to the aqueous suspension [54].
Similarly, liposomes of chloroquine, the widely used 4-aminoquinoline antimalarial, modified
with an antibody to selectively deliver to infected erythrocytes were found to cure the majority
of chloroquine-resistant Plasmodium berghei-malarial infections in mice [55], proving that
targeted liposomes can be very efficient in overcoming drug resistance. In the treatment of
systemic mycoses such as aspergillosis, there are few antifungal agents available, but due to
its broad spectrum of action amphotericin-B is potent against a wide range of fungi. In the
form of AmBisome and other related formulations (e.g. Abelcet and Amphocil) they are even
more effective in treatment of infections [56]. These formulations have also proved valuable
in treating Candida albicans infections in immunocompromised patients, eradicating an efficient
pathogen that is able to form fungal biofilms [57].
Understandably as the second most lethal infectious disease, many therapeutic cures for
tuberculosis (TB) have been available for over 50 years, but there are often patient issues with
the length of treatment and dose burden. As a result, treatment failures are common and can
promote the development of multi-drug resistant strains. Due to their potential to overcome
these problems, the development of drug carrying liposomes has become an important focus
in anti-tubercular studies. A ground-breaking study demonstrated that gentamicin loaded
liposomes had significantly greater antibacterial activity than the free drug, reducing the
bacterial load in the spleen and liver in a mouse model of Mycobacterium avium [58]. As well
as similar results utilising second-line antibiotics, lung-targeted liposomes were created
comprised of a mixture of phosphatidylcholine, cholesterol, dicetylphosphate, O-steroyl
amylopectin and monosialogangliosides, distearylphosphatidylethanolamine-poly(ethylene
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glycol) 2000 to deliver with less toxic effects, isoniazid and rifampicin for more efficient
chemotherapy [59]. As the predominant site of infection for TB is the respiratory system, many
efforts are now being made to develop aerosolised liposome formulations to successfully
deliver anti-tubercular drugs to the lungs by inhalation [60].
The strength of liposomes in supporting in the treatment of disease goes beyond purely as
drug delivery vehicles as they can be powerful tools to deliver vaccines, notably against viral
infections (Table 1). Significantly, liposomes can be engineered to deliver a variety of immu‐
nogenic molecules, whether protein, nucleic acid or carbohydrate to stimulate a strong
protective response. A notable commercially available preparation, Epaxal is a vaccine based
on inactivated intact Hepatitis A virus adsorbed on to liposomes (thus named virosomes)
which in a single dose are well tolerated and highly immunogenic giving good seroprotection
[61]. Marketed nearly twenty years ago, Inflexal V, a vaccine preparation against Influenza
virus consists of the viral heamagglutinin and neuraminidase surface proteins displayed in
phosphatidylcholine based liposomes [62]. In particular, Inflexal V mimicking a natural
influenza infection is a paradigm for liposome based vaccines with its safe but strong immu‐
nogenicity covering a wide range of ages and health conditions.
2.3. Other medical conditions
In addition to the treatment of disease, liposomes have the capability to aid in many other
medical-related conditions (Table 2). Notable examples of their use include in analgesia,
alleviation of macular degeneration, and as surfactants for pulmonary diseases. A variety of
liposome preparations have been marketed for use in analgesia or post-surgical pain-relief.
DepoDur and EXPAREL are liposome preparations of morphine and bupivacaine respectively
and when intravenously injected, demonstrate stability and extended release properties to give
prolonged anaesthesia or analgesia [63,64]. The typical therapy for neovascular age-related
macular degeneration requires repeated intravitreal injections of an anti-vascular endothelial
growth factor drug, effective in stabilising vision but an encumbrance for patients. The creation
of Visudyne, a liposome based formulation of the photosensitiser Verteporfin which requires
only intravenous injection has simplified patient treatment with relative success [65]. A
common problem in pulmonary diseases such as respiratory distress syndrome is a lack of
pulmonary surfactant, the phospholipid-protein complex needed to contribute a functional
respiratory surface at the mammalian lungs. Curosurf, a modified natural surfactant isolated
from pig lungs contains the essential phospholipid-associated surfactant proteins B and C, and
is widely used successfully in clinical treatment [66].
3. New approaches utilising synthetic lipids and fatty acids
3.1. Non-natural lipids and fatty acids
While having many advantages, natural liposomes utilised for the treatment of disease have
some drawbacks. Typically they are difficult to produce and are inherently unstable reducing
the potential storage time. In recent years a new generation of liposomes have been developed
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with altered biochemical properties designed to improve stability, functionalization and drug
release in addition to altered immunogenic and selective targeting properties. Construction of
these liposomes was only possible due to the use of non-natural fatty acids and lipids in the
particles. As an alternative to the standard inclusion of cholesterol in liposomes for increased
stability, a series of sterol-modified phospholipids were constructed [67]. These involved the
covalent attachment of cholesterol to the glycerol backbone of phosphatidylcholine, replacing
a fatty acid chain and resulting in sterol modified liposomes (SML). Other hydrophobic
molecules such as porphyrins and photosensitive agents can similarly replace a fatty acid
chain, [68]. In generating synthetic lipids, there are also many simple changes to the lipid
headgroup possible, vastly changing their chemical and biophysical properties [69]. Common
modifications can include the addition of a polymer, nucleic acid, carbohydrate, amino acid
or an assortment of functional chemical moieties for the downstream covalent attachment of
ligands.
3.2. Advantages of using synthetic lipids in liposomes
As mentioned above, liposomes incorporating synthetic lipids can have three main advantag‐
es, extended stability of the liposome, directed cell targeting and controlled release of the cargo
and examples of the modifications are discussed here:
Sterol modified liposomes carrying doxorubicin had similar therapeutic efficacy to the
standard Doxil in a colon carcinoma model, but with greater overall stability in circulation,
improved uptake into the liver and spleen [70]. This and other studies show the potential of
SMLs as drug delivery systems that are easy to synthesise from commercially available
molecules. Similarly the use of synthetic lipids incorporating porphyrins or photosensitive
agents to generate liposomes known as porphysomes which have applications in photody‐
namic therapy and diagnostics. Importantly these porphysomes demonstrate good pharma‐
cokinetics in mice, are safe at high doses, accumulate in tumours and can be imaged for
diagnostic purposes [68]. The use of the synthetic polyethylene glycol (PEG-2000) modified
1,2-distearoyl-sn-glycero-3-phosphoethanolamine in liposomes greatly altered the surface
hydrophilicity and by decreasing cell uptake, extended the circulatory half-life as mentioned
previously for Doxil [20].
Utilising liposomes constructed with synthetic lipids can create a number of novel functions.
In addition to the aforementioned polymer coating, modified headgroups are useful for the
attachment of cargo or specific ligand targeting. Often these modifications result in improved
targeting and biodistribution of liposomes by interacting with ligands present on specific cells
or tissue types. One notable example is nucleic acid modified lipids, which can result in the
physical interaction of the liposomes with single-stranded nucleic acids via base pairing. This
has proved biologically important in the efficient targeting of the nucleic acid binding drug
cisplatin to its site of action overcoming previous limitations in drug delivery and showing
potency against a number of sensitive and resistant cancer cell lines [71]. Liposomes have also
been generated using lipids synthesised with a range of functional groups to bind a number
of ligands. Most common is a maleimide lipid, although others with ester, ether, avidin, thiol,
hydrazine and carboxylic acid moieties in the headgroup have also been constructed [72]. The
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maleimide group can react with a free thiol and thus can allow liposomes to couple to any
exposed cysteine on a protein such as a single chain antibody. This approach has proved useful
in the modification of amyloid-β-targeting liposomes, made of sphingomyelin/cholesterol/
phosphatidic acid and functionalised through a terminal maleimide group on PEG-phospha‐
tidylethanolamine to display an anti-transferrin receptor antibody. This design gave the
liposomes the ability to cross an in vitro blood brain barrier model of human brain capillary
endothelial cells and thus hold huge potential for the successful delivery of therapeutics to the
central nervous system targeting amyloid-β and other defective proteins in Alzheimer’s
disease [73].
In an ideal scenario in the liposomal drug delivery system, the liposomes should be stable in
the circulation till they reach their destination and rapidly release their contents to have the
desired effect. In optimising the release of cargo from liposomes, a number of methods are
possible. Some such as altering the liposome formulation to destabilise the membrane or
increasing the hydrophilicity of the cargo are applicable to natural liposomes. However,
through the use of synthetic lipids, it is possible to control the release of liposome content with
various environmental cues, either external such as heat, light or ultrasound; or internal e.g.
pH or redox environment. This relies on the use of lipids to create liposomes that are sensitive
to specific stimuli to trigger the delivery of material at the appropriate time and place. This is
particularly useful in the delivery of small interfering RNAs (siRNA) where the use of pH
responsive ionisable lipids containing amine headgroups means that liposomes release the
nucleic acid only into the cytosol of the cell [74].
4. The use of lipids and liposomes as molecular tools
4.1. Molecules for imaging
The routine application of modified or synthetic lipids in liposomes and their subsequent
biocompatibility in vivo  or ex vivo  demonstrated that such particles could also be visual‐
ised through the incorporation of fluorescently tagged lipids. This methodology effective‐
ly replaces the original inconsistent approach of using liposomes carrying fluorescein as
cargo for imaging studies [75]. There are a number of commercially available synthetic lipid
species which have a fluorophore replacing a lipid fatty acid chain or alternatively replacing
or  conjugated  to  a  phospholipid  headgroup.  Common  fluorophores  attached  to  lipids
include non-polar 4,4-difluoro-4-bora-3α,4α-diaza-s-indacene (BODIPY), polar nitrobenzo-2-
oxa-1,3-diazole (NBD) and dansyl groups, hydrophobic pyrene and the highly fluorescent
rhodamine dyes [76]. Importantly, in selecting a fluorophore to use in labelling lipids and
liposomes, it is common to use dyes that emit light in the 650-1100nm far red/near infrared
region to avoid the conflict with the UV responsive autofluorescence of most eukaryotic
tissues. When fluorescent lipids are constructed into liposomes, the simple visualisation of
the labelled particles has aided in the study of a number of areas of research such as drug
delivery,  disease  diagnosis  and  membrane  fusion  events.  A  recent  study  using  fluores‐
cence microscopy specifically revealed that carbocyanine dye modified liposomes contain‐
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ing the antileishmanial agent meglumine antimoniate were taken up faster by Leishmania
major infected macrophages compared with non-infected cells, most likely due to parasite-
modified phagocytosis [77].  The attachment of the fluorescent curcumin molecule to 1,2-
dipalmitoyl-3-(2-(1,7-bis(4-hydroxy-3-methoxyphenyl)-3,5-dioxohept-6-enylthio)ethyl
phospho)-sn-glycerol  (DPS)  has  a  clinically  relevant  application  for  the  diagnosis  of
Alzheimer’s  disease.  As  curcumin  targets  the  Aβ  peptide,  injection  of  DPS-curcumin
containing liposomes into the brains of mice revealed the nanoparticles could successfully
target and stain the pathology causing Aβ deposits  in vivo  [78].  These types of  imaging
based studies  may be further  extended in a  dual  approach,  for  example in the efficient
bimodal  imaging  of  tumour  angiogenesis  through  the  use  of  rhodamine  conjugated
phosphatidylethanolamine  and  gadolinium-DTPA-bis(stearylamide)  lipids  for  optical
imaging and magnetic resonance imaging studies respectively [79]. These liposomes were
additionally constructed with RGD cyclic peptide moieties conjugated to maleimide-PEG-
DSPE, specifically to target the αvβ3 integrin highly expressed in angiogenesis. This and
other studies [reviewed in 80] have strongly validated the use of these modified lipids in
an effective streamlined approach for the in vivo visualisation and treatment of angiogene‐
sis, a critical process in metastatic tumour biology.
4.2. Immune system modulators
Due to their  biophysical  properties,  cell  targeting and entering abilities,  liposomes were
candidate adjuvants to aid in the modulation of the human immune system. Initially it was
observed that negatively charged liposomes of a certain composition of natural phospholi‐
pids carrying diphtheria toxin could induce an enhanced antibody response prior to release
of  the  true antigen [81].  Subsequently  this  use  was more deliberate,  for  example in  the
delivery of Shigella flexneri lipid A containing liposomes to stimulate an immune reaction
[82]. To date, the wide use of liposomes containing monophosphoryl lipid A has proved
highly  effective  in  safely  enhancing  immune  responses  to  candidate  vaccines  to  HIV-1,
malaria  and  a  number  of  cancers  [reviewed  in  83].  Significantly,  liposomes  have  been
developed to act as primary adjuvants, incorporating lipids whose headgroup is covalent‐
ly bound to antigens. Through the use of synthetic lipids like 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[4-(p-maleimidophenyl)butyramide],  a  range  of  peptide,
carbohydrate,  lipid and even antibody-like  molecules  can be attached [84].  These modi‐
fied liposomes can be administered via oral  or nasal  routes rather than injection and in
addition  to  little  or  no  toxicity  have  significant  capability  to  be  both  prophylactic  and
therapeutic vaccines.  One caveat however is that even early in liposome research it  was
clear that in certain circumstances any headgroup modified lipids could be adjuvants, and
based on the evidence to date, it is likely that most synthetic lipids will induce some sort
of immune response [69]. While the use of liposomes to stimulate the immune system to
exert a seroprotective effect as discussed is desirable, there are situations where an immune
suppressive  effect  may  be  desired.  A  directed  suppression  of  the  immune  system  is  a
desirable goal in the treatment of autoimmune disease, allergies and preventing the rejection
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of  organ  transplants.  Administering  liposomes  coated  in  the  bisphosphonate  aldronate
successfully  caused an  anti-inflammatory  effect  in  a  rabbit  model  through the  systemic
inactivation and depletion of macrophages and monocytes [85], similarly seen in models of
tissue  graft  rejection  [86]  and  arthritis  [87].  These  and  other  related  liposomes  based
strategies have great  potential  to deliver therapeutic  success in a safe manner for many
immune-related conditions [88].
4.3. Nucleic acid carriers
It is clear liposomes have an enormous ability to transport an assortment of molecules to
a variety of cells and tissue types and a rapidly expanding field is the delivery of nucleic
acid  into  cells.  In  genetic  modification,  the  delivery  of  genetic  material  to  augment  the
existing  genes  or  alternatively  silence  and/or  remove genes  has  become essential.  Some
current  approaches  to  deliver  genetic  material  into  cells  and  tissues  include  chemical-
based and viral based methods and can be inefficient with membrane permeability issues
and  potentially  cytotoxic  effects.  Particularly  in  exploring  the  concept  of  gene  therapy,
replacing  a  defective  copy  with  a  functional  wild-type  copy,  the  development  of  non-
viral based vectors to deliver nucleic acid into cells has focused on liposomes due to their
ability to carry large fragments of DNA and their low toxicity and immunogenicity. In the
development  of  liposome based nucleic  acid  delivery  systems,  it  was  discovered that  a
cationic  synthetic  lipid  N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium  chloride
(DOTMA) would form liposomes that would readily interact with negatively charged DNA
and stably hold it in the aqueous interior [89]. Typically cationic lipids have a positively
charged polar amino head group on top of a lipid-like hydrophobic domain. In contrast,
neutral or negatively charged lipid based liposomes can’t form electrostatic interactions to
bind and hold any negatively charged molecules. This ground-breaking research opened
up the field of using cationic liposomes to deliver material  and there are a now a wide
range of synthetic phospholipid and cholesterol analogues that generally form positively
charged liposomes [90].  Cationic  liposomes have  great  promise  as  nucleic  acid  delivery
agents  as  they  are  highly  efficient,  readily  interacting  with  negatively  charged  mem‐
branes for uptake into cells to deliver their cargo. Since the initial discovery, many cationic
liposomes have been used to deliver nucleic acids not just into cells in culture,  but also
animals  and  even  in  patients  in  phase  I  and  II  clinical  trials  though  with  some  dose-
dependent toxicity issues [90].
More recently, a revolution in the use of liposomes in nucleic acid delivery has come about
through the discovery of small interfering RNAs (siRNA). These siRNA are molecules which
are designed to bind the messenger RNA of a specific gene and thus silence its  expres‐
sion. This approach could potentially revolutionise the treatment of diseases such as cancer
where suppression of gene expression is of paramount importance. However, the use of
siRNA in a  clinical  setting has been restricted because the molecules  have a  short  half-
life,  show  poor  uptake  into  cells  and  are  rapidly  cleared  from  the  system.  Again  the
application of liposome technology has resurrected this form of therapy with the poten‐
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tial of liposomes specifically targeting the siRNA to the appropriate tissue in high concen‐
trations, preventing degradation of the molecule and therefore providing a safe non-toxic
delivery  system in  humans  and animals.  Typically  by  using  phosphatidylcholine  based
neutral liposomes, an efficient and stable targeted delivery of siRNAs into tumour tissues
was observed in a variety of animal models, significantly with a concomitant inhibition of
tumour growth [reviewed in 91].
4.4. Decoys for pathogens
Possibly  the  most  unusual  application  for  liposomes  comes  from  the  development  of
particles that when administered into an individual would impersonate the host cell type
recognised by invading pathogens,  trapping the  infectious  agent  and thus  reducing the
potential for disease. A recent example is the use of liposomes bearing the glycan sialylneo‐
lacto-N-tetraose c (LSTc), an analogue of the influenza virus targeting sialic acid molecule
found on the surface of respiratory tract cells. Decoy liposomes containing LSTc conjugat‐
ed  to  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine  successfully  bind  influenza  virus
particles in competition assays in culture and in a mouse model prevent virus spread and
increase the survival time even under challenge of a lethal dose [92]. This is significantly
better than using free sialic acid analogues, which have shown some success, but are not
suitable due to toxicity and solubility issues. Importantly due to their mode of action, the
decoy liposomes should have the ability to successfully target both newly emerging and
established drug resistant influenza strains without discrimination. This approach has the
possibility to become a key preventative treatment against a wide range of pathogens that
target specific cell surface receptors.
5. Lipid analogues as cytotoxic molecules
5.1. Alkyllysophospholipids
Of all  the  lipid  analogues  that  have  be  synthesised  to  date,  the  alkyllysophospholipids
(ALPs) are probably the most studied for their toxicity to cells. This series of ether lipids
was  born  out  of  the  observation  that  the  natural  lipid  lysophophatidylcholine  (lysoPC)
possessed potent immunomodulatory properties but was rapidly metabolised, reducing its
effectiveness [93]. To increase the stability but retain the activity of this molecule, lysoPC
analogues were synthesised that incidentally had inhibitory effects on tumour growth [94].
With a chemical structure containing a long alkyl chain, ALPs insert into the lipid bilayer
of cell membranes and act similarly to a detergent at high concentrations causing cell lysis.
At more physiologically relevant concentrations, ALPs have a number of biological effects
relating to  the  disruption of  cell  membranes,  including influencing membrane domains,
phospholipid turnover and lipid associated signalling pathways [95]. The consequences of
these diverse modes of action include growth inhibition, cell  stress,  cell  cycle arrest and
Lipids and Liposomes in the Enhancement of Health and Treatment of Disease
http://dx.doi.org/10.5772/59665
143
apoptosis. The most commonly studied ALPs are listed in table 3 showing the timeline of
their development and primary publications. For their chemical structures see [95].
Alkyllysophospholipid Year Targeted disease Ref.
Edelfosine (ET-O-CH3) 1967 Cancer, Leishmaniasis, Human African
Trypanosomiasis
96
Miltefosine (HePC) 1983 Cancer, Leishmaniasis, Human African
Trypanosomiasis
97
Ilmofosine 1984 Cancer, Leishmaniasis, Human African
Trypanosomiasis
98
Erucylphosphocholine (ErPC) 1992 Cancer 99
Perifosine (D-21266) 1997 Cancer, Leishmaniasis 100
Erufosine (ErPC3) 2002 Cancer 101
Table 3. Common alkyllysophospholipids used for disease treatment.
5.2. Anticancer
The first ALP to be studied in detail, edelfosine was demonstrated to have a cytotoxic effect
on a wide range of cell types, both tumour derived and normal [96]. However it was apparent
that edelfosine demonstrated a high selectivity towards tumour cells, strongly stimulating
apoptosis by an unknown mechanism. Over the next forty years a number of analogues of
edelfosine were similarly investigated for their cytotoxic anti-cancer properties. Although the
most potent of the ALPs, the clinical use of edelfosine has remained limited to the treatment
of acute leukaemia patients in the purging of bone marrow prior to autologous tissue trans‐
plantation [102]. Miltefosine, even though it is metabolised in cells unlike the other ALPs, still
has potent anti-tumour activity in some animal models [103]. Unfortunately due to its
haemolytic properties, its clinical use is restricted as a topical formulation, promising in phase
II trials in the treatment of cutaneous metastases of breast cancer [104]. The most recent ALPs,
the homologous erucylphosphocholine and erufosine are suitable for intravenous injection
having longer 22 carbon chains and a double bond which causes them to associate in aqueous
environments as non-haemolytic lamellar rather than micellar structures. They are valued
ALPs in the development of cancer treatments as they have the ability to cross the blood-brain
barrier, accumulate in the brain and show anti-tumour effects both in vitro [105] and in vivo
[106]. Perhaps the ALP with the most therapeutic potential, perifosine, created by replacing
the choline in miltefosine with a heterocyclic piperidine group, demonstrated good pharma‐
cokinetics and strong cytotoxicity against a wide variety of tumours [107]. Its poor performance
in single agent phase II trials however, has stimulated its use in successful application in
combination with various anti-tumour treatments that affect other pathways in the cell.
Perifosine has showed highly promising anticancer therapy in combination with inhibitors of
the anti-apoptotic mTOR signalling network. Individually, drugs targeting mTOR are less
effective as often the inhibition is overcome through induction of a positive feedback loop by
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the protein kinase Akt to upregulate mTOR [108]. The additive effect generated with the
combinational approach is due to perifosine inhibition of Akt causing suppression of the
positive feedback loop.
5.3. Antifungal
In the treatment of invasive mycoses, the use of miltefosine has demonstrated some broad
spectrum fungicidal activity in vitro and in a mouse model of cryptococcosis [109]. In general
however the application of ALPs to treat fungal infections in humans has been restricted by
the limited therapeutic effect against cryptococcal infections in animals [110]. This may be in
part due to their apparent mode of action in inhibiting cytochrome C oxidase in Saccharomyces
cerevisiae and phospholipase B in Cryptococcus neoformans, two non-essential yeast proteins
[109,111]. The use of ALPs as potent antifungal agents might be resurrected in part by two
recent developments. The synthesis of new analogues based on existing structure–antifungal
activity relationship (SAR) information of ALPs has given hope that this class of compounds
can have benefit in the treatment of invasive or device-related fungal infections [112]. Fur‐
thermore, in a study of combinational therapeutics, some synergy was observed in a number
of fungal strains with miltefosine and the broad-spectrum drug voriconazole which may
develop with further research into clinical relevance [113].
5.4. Antiparasitic
It is in the field of parasitology where the ALPs have shown great promise. Initially, alongside
their anti-cancer effects, a range of ALP analogues were found to have strong anti-protozoal
activity against the free-living ciliate Tetrahymena pyriformis [114] and Leishmania donovani, the
causative agent of visceral leishmaniasis [115]. Subsequent research demonstrated that
different ALPs had varying potency against different protozoan species and lifecycle stage. In
general however a range of Leishmania species, Trypanosoma brucei and T. cruzi parasites have
showed significant susceptibility to these ALPs with effective dose killing responses in the low
micromolar range [reviewed in 116]. The development of ALPs as potential anti-parasitic
drugs in a clinical setting came from the discovery that miltefosine completely prevented L.
donovani infection in mice with very little side effects [117]. Ultimately this research led to the
development of a clinically approved formulation of miltefosine, Impavido in 2000, still to date
the only approved oral drug for leishmaniasis [118]. Impavido is approved for the treatment
of cutaneous and mucosal leishmaniasis but is particularly utilised for the first-line treatment
of endemic visceral leishmaniasis in Asia. In addition, the use of miltefosine has been shown
to be effective in curing patients infected with L. donovani parasites unresponsive or resistant
to antimony treatment [119]. Similar to the anti-cancer effects of ALPs, the mode of action of
miltefosine against Leishmania spp. is not entirely clear. There is a notable structural damage
to the plasma membrane of most ALP treated parasites, suggestive of alterations to the lipid
content [116]. Recent modern metabolomic approaches have defined cellular changes in
miltefosine action against Leishmania and indicate disruption of the lipid metabolism of the
cells as a primary target [120]. Issues with the development of resistance to miltefosine (partly
due to weak therapeutics and rapid metabolism) have led to the development of ALP loaded
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liposomes. These have proven to be more active than the ALP alone in the treatment of animal
models and as in other studies they have shown efficacy against the drug-resistant cell lines
[121]. It is clear that the combined use of liposomes and ALPs is a powerful tool, giving a
potential dual target approach to combat parasite infection and drug-resistance.
6. Lipids and liposomes in health and nutrition
6.1. Fatty acids and lipids
It is well documented that omega-3/omega-6 polyunsaturated fatty acids (PUFA) are essential
for normal growth and development, especially for visual and neurological development in
infants [122, 123]. These fatty acids have also been shown to have numerous beneficial effects
on various aspects of human health, and as such the recommended minimal daily intake is set
at 250 mg [124]. As humans we are unable to de novo synthesise omega-3 PUFA, as we do not
have the necessary fatty acid desaturase enzyme(s) and thus rely solely upon dietary intake
of these PUFA. Two crucial PUFAs are eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), these are primarily accessed via marine sources, i.e. fish or krill oil, while α-linolenic
acid (ALA), is found in numerous plant sources such as nuts and seeds. The biological activities
of omega-3/omega-6 PUFA have been under extensive study for several decades and their
beneficial effects on several diseases have been well documented, some of which will be now
be discussed.
Dietary changes in fatty acid composition have been show to change the proportion of different
types of PUFA in inflammatory and immune cells and thus influencing their function, this is
thought to be because they can act as precursors to lipid mediators (eicosanoids/docosanoids)
or as ligands for transcription factors [125]. Various omega-3 supplements also seem to boost
the effectiveness of anti-inflammatory drugs, several clinical studies have reported that fish
oil supplementation has beneficial effects in rheumatoid arthritis, inflammatory bowel disease,
and among some asthmatics, supporting the idea that omega-3 PUFA trigger anti-inflamma‐
tory and immunomodulatory activities [126]. Along the same lines the PUFA arachidonic acid
(AA) is a precursor for prostaglandins, leukotrienes, and related compounds acting as
secondary messengers, modulating various roles in inflammation and immunity. Even
gamma-linolenic acid a non-essential fatty acid, present in high levels in borage oil has been
shown to have several beneficial effects in the treatment of rheumatoid arthritis, atopic eczema
and diabetic neuropathy, as well as in the reduction of cholesterol levels [127].
The  changing  diet  of  Western  societies  since  industrialisation  has  been  argued  to  have
promoted the pathogenesis  of  many inflammatory-related diseases,  including depressive
disorders. Researchers have found a correlation between cultures that eat foods with high
levels of omega-3 PUFA also have lower levels of depression [128]. Several epidemiologi‐
cal studies have also shown a significant inverse correlation between intake of oily fish and
depression  and  bipolar  disorders  [128,  129].  However  it  has  been  suggested  that  the
preventive role of omega-3 PUFA may depend on other factors, such as overall diet quality
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and the social environment. Accordingly, some research suggests that omega-3 PUFAs may
be effective in several ways in protecting people against Alzheimer's disease and demen‐
tia  by  reducing  the  rate  of  gradual  memory  loss  linked  to  aging  and  enhancing  the
effectiveness of antidepressants [130].
It is common knowledge that fish and fish oil consumption (high in omega-3 PUFA) can
significantly reduce the risk of cardiovascular diseases (CVDs) and slow the formation of
plaque in the arteries [131].  It  is now becoming clear that it  is increasingly important to
know which fatty acids especially EPA and DHA are attached to which lipid species. This
has  recently  become  apparent  as  no  significant  statistically  correlation  is  observed  be‐
tween omega-3 PUFAs and the reduced risk of cardiovascular diseases (CVDs) when 20
studies on 68680 patients were re-evaluated. The latest evidence suggests the true biologi‐
cally active component, or parent lipid species, has a direct influence on its delivery and
subsequent  usage/in  vivo  activity  [132  and  references  therein].  Despite  the  various  and
numerous biological activities of omega-3 PUFA and their corresponding health benefits
being extensively studied for several  decades.  However,  the potential  different forms in
which these could be delivered via dietary intake such as triglycerides (TGs) versus ethyl
esters or phospholipids (PLs), has largely been neglected. The fatty acid chain length and
unsaturation on the lipids affects their intestinal absorption efficiency, whereas the chemical
structure  of  the  lipids  (TGs  versus  PLs)  determines  their  digestion  products  prior  to
absorption.  The  enrichment  of  essential  fatty  acids  in  particular  phospholipids  for  in‐
creased dietary uptake and nutritional  activity in the body is  important.  Several  studies
show evidence that dietary PLs have a positive impact in several diseases and potentially
reduce side effects of some drugs [133, 134].
Modern diets are often depleted of complex and diverse mixtures of PLs due to increased use
of refined oils and purified raw materials, which had led to an overall reduction in the uptake
of PLs. Hence, the supplementation of marine PLs may serve three important functions within
the functional food segment: (a) emulsifying properties, (b) supplementation of omega-3
PUFAs and (c) beneficial nutritional effects of the PLs themselves [135]. A better understanding
of the impact of PL supplementation and its health benefits is required.
The potential anti-obesity effect of conjugated linoleic acid, and its mode of action lowering
body fat mass has recently been reviewed by Kennedy et al [136]. Conjugated linoleic acid
(CLA), a group of conjugated cis and trans isomers of octadecadienoic acid that have been
converted from linoleic acid by microbes in the gastrointestinal tract of ruminant animals and
often found in beef, dairy foods, and dietary supplements, reduces adiposity in several animal
models of obesity and in some humans. CLA was discovered by Pariza and colleagues in 1987,
and was first identified as an anti-carcinogen, but subsequently shown to exhibit anti-
atherosclerotic and more recently anti-obesity properties [137]. Interest in CLA as an alterna‐
tive treatment to conventional diabetic and weight loss therapies has increased over the past
decade. Supplementation with a mixture of CLA isomers decreased the body fat mass in many
animal and some human studies. The major 10,12 isomer of CLA, seems to be responsible for
the antiobesity effects. Commercial preparations of CLA are now made from the linoleic acid
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of safflower or sunflower oils under alkaline conditions. Kennedy et al have summarised the
recent in vivo and in vitro findings and propose potential mechanisms by which CLA reduces
adiposity including its impact on energy metabolism, adipogenesis, inflammation, lipid
metabolism, and apoptosis [136].
6.2. Liposomes
Liposomal encapsulation technology used by medical researchers to deliver drugs effective‐
ly to specific areas or organs in the body, as discussed earlier, is also being used to target
delivery  of  a  number  of  poorly  soluble  and  high  molecular  weight  bioactive  dietary
components including natural products such as carotenoids, phytosterol, omega-3 PUFAs,
vitamins and other antioxidants to the body. The liposomes provide a number of advantag‐
es to other delivery systems and this is why a number of nutritional companies are now
utilizing this technique in the oral delivery of dietary supplements and nutrients that are
not  prematurely  decomposed  and  are  pinpointed  to  specific  tissues  and  organs.  This
approach has the added bonus that the doses can be reduced by 5 to 15 times less than
normal supplement intake, i.e. tablets and capsules. The beneficial action of liposomes in
oral  delivery  of  nutrients  is  due  to  several  modes  of  their  action,  including  improved
nutrient solubilisation and protection against environmental conditions such as moisture,
oxygen and degradation by the presence of enzymes in oral and esophageal digestive juices
prior to being absorbed into the body [138-140]. The phospholipids of the liposomes are
able to repel undesirable activities of the digestive juices of the gastrointestinal tract, until
the contents have reached the target tissue and are endocytosed, delivering their cargo into
the intra-cellular space. It is important to note that more conventional delivery routes for
nutrients, such as tablets, capsules etc., offer different and complementary forms of nutrient
bio-availability, however the various food additives used in tablets and capsules, such as
binders,  fillers,  gelatins  and  sugar  affect  the  absorption  process  and  may  cause  incom‐
plete disintegration, hence reducing bioavailability of the active components.
More than 50 products and product combinations have been formulated using liposomal
delivery systems, some of them are listed in Table 4. A key example of the full potential of
using oral liposomal encapsulation is vitamin C, which causes a ~10-fold increase of vitamin
C into cellular systems compared to oral tablet/capsule formulations, with no negative effects,
such as gastric distress, urinary output or extra load on the liver [141].
Vitamin/herb/botanical Active compound(s) Health benefits
Vitamin A Retinol Retina function, Epithelial tissue growth, Bone growth, Embryonic
development
Vitamin B2 Ribofiavin Essential for metabolizing carbohydrates, fats, and lipids
Necessary for the function of vitamins B6, folic acid, and niacin
Vitamin B12 Cyanocobalamine Deficiency causes pernicious anemia, muscle and nerve paralysis
Vitamin C Ascorbic acid Antioxidant
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Vitamin/herb/botanical Active compound(s) Health benefits
Vitamin E alpha-Tocopherol Detoxifies free radicals, Prevents damage to cell membranes.
Enhances immune response,
Antioxidant
CoEnzyme Q10 Ubiquinone-50 Increased mitochondria function, cofactor in oxidative respiration
DHEA Dihydroepiandrosteindione Increased libido, Feelings of well being Decreased viral load
Echinacea Echinacosides Immuno-stimulation
Gingko biloba extract Gingolides Dementia, Equilibrium disorders,Intermittent claudication
Glucosamine sulfate Glucosamine Osteoarthritis, Bone, cartilage, and Muscle growth
Grape seed extract Procyanidines Antioxidant, Inhibits tooth decay, Source of essential oils
IGF-1 Insulin, Growth Factor-1 Anti-aging
Kava kava Kava lactones Anxiolytic, insomnia
Ma huang Ephedra Cough, Bronchitis, Appetite suppression
Melatonin Melatonin Insomnia, Jet lag
Milk thistle Silymarin Hepatoprotection, Cirrhosis, Hepatitis, Immunomodulation
St. Johns wort Hypericin, pseudohypercin Anxiolytic, Depression, Topical inflammation, Wound healing
Zinc gluconate, zinc
sulfate
Zinc ion Essential part of more than 200 enzymes involved in digestion,
metabolism, reproduction (sperm formation), and wound healing.
Involved in sense of taste. Role in function and structure of cell
membranes. Major part of the immune system. Component of insulin
deficiency
Table 4. Liposomal nutritional products on the market
Dietary polyphenols, including flavonoids, have long been recognized as a source of important
molecules involved in the prevention of several diseases, including cancer. However, due to
their poor bioavailability, polyphenols remain difficult to be employed clinically. The recent
use of liposomes, as a means of improving their pharmacokinetics and pharmacodynamics,
hence their bioavailability means there is a renewed interest into the therapeutic benefits of
wide range of polyphenols [142, 143].
7. Future perspectives
Liposomes are being used in a wide range of applications from drug and gene delivery to
diagnostics, cosmetics and food nanotechnology being able to be administrated orally,
parenterally or topically. Liposome formation and entrapment of various different types of
cargo is now a well established methodology, allowing them to stabilise the encapsulated
materials against a range of environmental and chemical changes, including enzymatic and
chemical modification, as well as buffering against extreme pH and temperature [144].
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There are a rapidly increasing number of new applications for liposomes in the drug and food
industry, due to their biocompatibility and biodegradability. The natural composition of the
liposomes, which helps in overcoming regulatory hurdles, and if required newly developed
formulations can quickly be implemented. However, use of multiple lipid sources (e.g. animal,
plant, synthetic sources) often requires additional characterisation and comparability studies.
The quality and purity of the lipid starting materials for lipsome formulations are essential to
maintain the quality of the later drug or encapsulated product. Therefore the appropriate
characterization and specification of the lipid starting material is considered as vital as the
product being delivered, as laid out by EU directive 2001/83/EC, along with guidance on
process validation CHMP/QWP/848/99 and EMEA/CVMP/598/99 and marketing authorisa‐
tion of a medicinal product (EMEA/CHMP/QWP/396951/2006).
The remarkable biocompatibility of liposomes probably stems from the fact that they are
closely analogous to both naturally occurring endosomes that circulate in the bloodstream
before accumulating in specific tissues, and lamellar bodies known to lubricate and protect
tissue surfaces and serve in specialist functions, i.e. act a surfactant in the lungs to allow oxygen
to pass from the air into the bloodstream. The depletion of lamellar bodies is also implicated
in a range of diseases, including serious progressive respiratory conditions, including Cystic
Fibrosis and Chronic Obstructive Pulmonary Disease [144]. These are obvious areas of research
where liposome technology could be a game changer.
In order to extend and take full advantage of this highly biocompatible and safe biodegradable
delivery system, future research should focus on the production of the lipid vesicles through
safe, scalable methods, as well as accessing the required high quality/purity of lipids in a cheap
and sustainable manner.
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